ABCC3 and metabolic dysfunction-associated steatohepatitis: Mrp3 protein expression increased to 425% of control in the WT-NASH group, to 245% of control in the Mrp2–/–-NASH group, and to 386% of control in the O–/–-NASH group (Fig. 5A and B, lower right panels).